Evidence Hub

Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study

James B. Wetmore, E. Weinhandl, Heng Yan, Jorge L Reyes, C. Herzog, N. Roetker

American Journal of Kidney Diseases, 2022

17,156 participants · 47 citations

Abstract

BACKGROUND & OBJECTIVES

Comparison of clinical outcomes across anticoagulation regimens using different apixaban dosing or warfarin is not well-defined in patients with nonvalvular atrial fibrillation (AF) who are receiving dialysis. This study sought to compare these outcomes in a US national cohort of patients with kidney failure receiving maintenance dialysis.

STUDY DESIGN

Retrospective cohort study.

SETTING AND PARTICIPANTS

Patients receiving dialysis represented in the USRDS database 2013-2018 who had AF and were treated with apixaban or warfarin.

EXPOSURE

First prescribed treatment with Apixaban dosed according to the label, apixaban dosed below the label, or warfarin.

OUTCOMES

Ischemic stroke/systemic embolism (SE), major bleeding, and all-cause mortality.

ANALYTICAL APPROACH

Cox proportional hazards models with inverse probability of treatment weighting. Analyses simulating an intention-to-treat (ITT) approach as well as those incorporating censoring at drug switch or discontinuation (CAS) were also implemented. Inverse probability of censoring weighting was used to account for possible informative censoring.

RESULTS

Among 17,156 individuals, there was no difference in risk of stroke/SE among the label-concordant apixaban, below-label apixaban, and warfarin treatment groups. Both label-concordant (HR 0.67, 95% CI 0.55-0.81) and below-label (HR 0.68, 0.55-0.84) apixaban dosing were associated with a lower risk of major bleeding compared to warfarin in ITT analyses.…

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 17,156 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free